Antibody clues after stem cell transplants could prevent rejection
NCT ID NCT06395220
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 314 people with blood cancers who received stem cell transplants from mismatched donors. Researchers tracked donor-specific antibodies after transplant to see how often they appear and what factors influence them. The goal is to better understand and prevent graft rejection or poor graft function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could help doctors better predict and prevent graft rejection or poor graft function after stem cell transplants.
- What could go wrong
- This is an observational study, not a treatment trial. It aims to gather knowledge, not test a new therapy, so there is no direct benefit to participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMATOLOGICAL MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
People's Hospital of Peking University
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cancer care goes home: study tests nurse visits to cut hospital trips
- Blood cancer chemo and adrenal risk study pulled before start
- Can a simple drink help blood cancer patients recover from stem cell transplants?
- Are CLL patients getting fair referrals? new study investigates
- Could existing cancer drugs tackle rare tumors? new trial aims to find out
- Could a breast cancer drug combo treat rare tumors?